---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055585"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:50:08.090308+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M

## Summary
- Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.
- Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.
- Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.
- Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.
- NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted.

## SEC filing metadata
- accession: 0000950170-24-055585
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/0000950170-24-055585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/psnl-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055585
- JSON: https://secwatch.observer/filing/0000950170-24-055585.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055585.txt

## Key facts
- Earnings Releases
  Personalis, Inc. reported first quarter of 2024 ended March 31, 2024 results: revenue total company revenue of $19.5 million, net income Net loss of $13.0 million. Guidance raised.
  - Period: first quarter of 2024 ended March 31, 2024
  - Revenue: total company revenue of $19.5 million
  - Net income: Net loss of $13.0 million
  - Guidance: raised
  - Result: reported results
  source text: delivered in Q1, reflecting 100% engagement of NeXT Personal Dx early access clients and strong NeXT Dx growth. “We began 2024 with strong execution as we delivered revenue of $19.5 million in the first quarter, exceeding the upper-end of our guidance range, and we continue to develop compelling NeXT Personal clinical evidence as we work towards obtaining Medicare
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017024055585/0000950170-24-055585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.